Last reviewed · How we verify
Infective mosquito bite
Infective mosquito bite is a Biologic drug developed by Medicines for Malaria Venture. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Infective mosquito bite |
|---|---|
| Sponsor | Medicines for Malaria Venture |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults (NA)
- DSM265 Prophylaxis of Plasmodium Falciparum Malaria (PHASE1)
- Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54 (PHASE1)
- Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans (PHASE1)
- Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites (PHASE1, PHASE2)
- Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infective mosquito bite CI brief — competitive landscape report
- Infective mosquito bite updates RSS · CI watch RSS
- Medicines for Malaria Venture portfolio CI
Frequently asked questions about Infective mosquito bite
What is Infective mosquito bite?
Who makes Infective mosquito bite?
What development phase is Infective mosquito bite in?
Related
- Manufacturer: Medicines for Malaria Venture — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing